表紙
市場調査レポート

メタボロミクス:技術と世界市場

Metabolomics: Technologies and Global Markets

発行 BCC Research 商品コード 261643
出版日 ページ情報 英文 202 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.39円で換算しております。
Back to Top
メタボロミクス:技術と世界市場 Metabolomics: Technologies and Global Markets
出版日: 2015年11月30日 ページ情報: 英文 202 Pages
担当者のコメント
BCC Research社のレポートは、Reuter、Wall Street Journal、Fortuneなどで引用されることも多く、それぞれの業界の識者の意見として重きを置かれています。同社レポートを複数冊ご購入の場合年間パッケージのご契約がお得です。詳細は右の担当者のおすすめ商品よりご覧下さい。
概要

世界のメタボロミクス市場は、2014年に59億米ドル規模となり、2015年に68億米ドルおよび2020年までに125億米ドルに達し、予測期間中は13.0%のCAGRを示すと予測されています。

当レポートでは、世界のメタボロミクス市場および技術について調査し、メタボロミクス研究分野の商業的可能性、市場動向の実績データと今後のCAGR予測、メタボローム・メタボライト・メタボロミクスvs.メタボノミクスの定義、メタボロミクスの概念的アプローチ、メタボロミクス市場の主要構造 (セグメント・主要アプリケーション分野・市場参入企業) 調査、メタボロミクスの分離技術 (ガスクロマトグラフィー・キャピラリー電気泳動・HPLC) 、特許分析および主要企業のプロファイルなどをまとめ、お届けいたします。

第1章 イントロダクション

第2章 サマリー

第3章 メタボロミクスの概要

  • 代謝産物 (メタボライト)
  • メタボロミクス
  • メタボロミクスの歴史
  • メタボロミクスの基本
  • 異化経路・同化経路
  • アデノシン三リン酸 (ATP)
  • 酵素の役割
  • フィードバック阻害
  • ミトコンドリアに位置
  • 酸化・還元反応
  • 脱水素酵素
  • 電子伝達鎖
  • 酸化的・基質レベルのリン酸化
  • 解糖
  • クレブス回路
  • アセチル補酵素A
  • 電子伝達:フラビタンパク質・シトクロム
  • TCAサイクル
  • アデノシン3リン酸 (ATP) 合成
  • 発酵
  • アプリケーション
  • 課題
  • 分析技術
  • パフォーマンス促進因子
  • 市場の2次区分、ほか

第4章 メタボロミクス分析プロセス・装置

  • メタボロミクスのプロセスステップ
  • メタボロミクス分析の手順
  • サンプル調製・抽出に用いられる機器
  • 分離・検出製品
  • 分離
  • 検出
  • ハイフネーテッドアプローチ
  • ガスクロマトグラフィー質量分析
  • 液体クロマトグラフィー質量分析
  • キャピラリー電気泳動質量分析
  • 新しい検出技術
  • 分析装置市場
  • メタボロミクス市場で用いられる分析装置

第5章 アッセイのコンポーネントおよびメタボロミクスのキット

  • 標的メタボロミクス
  • 本章の調査範囲
  • アッセイの概要
  • アッセイ・アッセイキットの背景
  • バイオケミカルアッセイ
  • アッセイの商業的検討事項
  • アッセイ検出の概要
  • セルベースアッセの商業的状況
  • メタボロミクス研究に用いられる主なエッセイのタイプ
  • 代謝に用いられるアッセイ
  • 酸化・還元反応
  • 創薬の利用
  • ツール・技術
  • 新しい分析ツール
  • 導入動向
  • 関連アプリケーションにおけるアッセイ
  • 細胞毒性:主な分類
  • 細胞生存・生存のための代謝アッセイ
  • 細胞死のためのアッセイ
  • 細胞増殖抑制性または長期的影響のためのアッセイ
  • マルチアッセイ、ほか

第6章 メタボロミクスにおけるバイオインフォマティクス

  • 概要
  • バイオインフォマティックプロセス
  • データ構成分析・処理
  • データ削減・統合
  • データモデリング
  • データ仮想化
  • データベースキュレーション・管理
  • メタボロミクスの公的資金
  • 商業市場の構造
  • 自社でソフトウェアを開発する企業
  • 市場

第7章 臨床バイオマーカー

  • 概要
  • バイオマーカーの課題
  • プロテオミクスからの進歩
  • メタボロミクスのメリット
  • アプリケーション導入
  • 主な臨床アプリケーション
  • 薬理ゲノミクス
  • 肝臓酵素
  • クロピドグレル
  • ヒト白血球抗原B
  • カルバマゼピン
  • アザチオプリン
  • メンタルヘルス
  • セロトニン
  • カテコールメチルトランスフェラーゼ
  • 薬理動態・薬物力学遺伝子
  • 商業事例
  • 課題・将来の方向性
  • 心血管・代謝疾患
  • 肝疾患
  • 商業上の検討事項

第8章 企業プロファイル

図表リスト

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: BIO055B

REPORT HIGHLIGHTS

The global metabolomic market totaled $5.9 billion in 2014 and should total $6.8 billion in 2015 and $12.5 billion by 2020, registering a compound annual growth rate (CAGR) of 13.0%.

This report provides:

  • An overview of the commercial potential of the metabolomics research field, the systematic study of the unique chemical fingerprints that cellular processes leaves behind
  • Analyses of global market trends, with data from 2014, estimates for 2015 and projections of compound annual growth rates (CAGRs) through 2020
  • Definitions of metabolome, metabolites, and metabolomics vs. metabonomics
  • Discussion of the conceptual approach in metabolomics: target analysis, metabolite profiling, metabolomics, metabolic fingerprinting
  • Examination of the main structure of the metabolomics market: segments, key application areas, and market participants
  • Separation techniques for metabolomics: gas chromatography, capillary electrophoresis, and high-performance liquid chromatography (HPLC)
  • Patent analysis
  • Company profiles of major players in the field

SCOPE OF REPORT

The scope of the report encompasses the major metabolomic technology types that have been used, as well as the major applications being developed by industry, academic researchers and their commercialization offices, and government agencies. It analyzes current market status, examines future market drivers and presents forecasts of growth over the next five years. Technology developments, including the latest trends, are discussed. Other influential factors such as screening strategies for pharmaceuticals have also been included.

ANALYST'S CREDENTIALS

Robert G. Hunter has more than 20 years of experience in life sciences as an analyst, business development executive, project manager and management consultant for business processes, organizational development and systems implementation. His recent BCC Research reports include BIO140A 3D Cell Culture: Technologies and Global Markets, and PHM017E In Vitro Toxicology, which also covered in silico applications and the status of predictive medicine. His studies have included multiple stem cell lines for true genetic diversity and proteomic biomarkers for cancer via label-free imaging. He is an early investor in a company using stem cells for in vitro screening of pharmaceutical compounds.

Table of Contents

CHAPTER 1 - INTRODUCTION

  • STUDY GOALS AND OBJECTIVES
  • REASONS FOR DOING THE STUDY
  • SCOPE OF REPORT
  • INTENDED AUDIENCE
  • INFORMATION SOURCES
  • ANALYST'S CREDENTIALS
  • RELATED BCC RESEARCH REPORTS
  • BCC RESEARCH WEBSITE
  • DISCLAIMER

CHAPTER 2 - SUMMARY

  • SUMMARY TABLE: GLOBAL METABOLOMIC MARKET BY APPLICATION, THROUGH 2020 ($ MILLIONS)
  • SUMMARY FIGURE: GLOBAL METABOLOMIC MARKET BY APPLICATION, 2014-2020 ($ MILLIONS)

CHAPTER 3 - OVERVIEW OF METABOLOMICS

  • METABOLITES
  • METABOLOMICS
  • METABOLOMIC HISTORY
    • TABLE 1: HUMAN METABOLOME PROJECT AND DATABASE, 2006-2013
  • METABOLISM BASICS
  • CATABOLIC AND ANABOLIC PATHWAYS
    • TABLE 2: CELLULAR RESPIRATION STAGES
  • ADENOSINE TRIPHOSPHATE
  • ENZYME ROLE
    • TABLE 3: FACTORS IMPACTING ENZYME ACTIVITY
  • FEEDBACK INHIBITION
  • LOCATED IN MITOCHONDRIA
  • OXIDATION AND REDUCTION REACTIONS
  • DEHYDROGENASES
  • ELECTRON TRANSPORT CHAIN
  • OXIDATIVE AND SUBSTRATE-LEVEL PHOSPHORYLATION
  • GLYCOLYSIS
  • KREBS CYCLE
  • ACETYL COA
  • NADH AND FADH2 DONATE ELECTRONS
  • ELECTRON TRANSPORTERS: FLAVOPROTEIN AND CYTOCHROMES
  • TRICARBOXYLIC ACID CYCLE
  • ADENOSINE TRIPHOSPHATE SYNTHESIS
  • FERMENTATION
  • FOOD TO ENERGY
  • LIPID PROCESSING
  • FATTY ACID BETA-OXIDATION IN THE HEART
  • KETOSIS
    • BENEFITS
  • METABOLOMES
    • LARGE BOWEL MICROFLORA
    • URINE METABOLOME
    • FOOD METABOLOME
  • LIPIDOMICS
  • FLUXOMICS
  • APPLICATIONS
  • CHALLENGES
  • ANALYTICAL TECHNOLOGIES
  • PERFORMANCE DRIVERS
    • LIMITS OF DETECTION
    • TARGETED VERSUS UNTARGETED APPROACHES
    • TARGETED ANALYSIS
    • METABOLITE PROFILING
    • METABOLIC FINGERPRINTING
    • UNTARGETED APPROACHES
  • MARKET SUB-SEGMENTS
    • TABLE 4: PUBLICATIONS USING KEYWORD METABOLOMICS IN THE SEARCH, 2002-2014 (TOTAL PER YEAR)
    • FIGURE 1: PUBLICATIONS USING KEYWORD METABOLOMICS IN THE SEARCH, 2002-2014 (TOTAL PER YEAR)

CHAPTER 4 - METABOLOMIC ANALYTICAL PROCESSES AND INSTRUMENTS

  • METABOLOMIC PROCESS STEPS
    • TABLE 5: TYPICAL ANALYTICAL METRABOLOMIC PROCESS STEPS
  • METABOLOMIC ANALYSIS PROCEDURES
    • SAMPLE PREPARATION
    • EXTRACTION
    • DERIVATIZATION
    • SEPARATION AND DETECTION
    • DATA ANALYSIS
  • EQUIPMENT USED IN SAMPLE PREPARATION AND EXTRACTION
  • SEPARATION AND DETECTION PRODUCTS
  • SEPARATION
    • CHROMATOGRAPHY
      • High-Performance Liquid Chromatography
      • Gas Chromatography
    • CAPILLARY ELECTROPHORESIS
    • SEPARATION EQUIPMENT MARKET
    • SUPPLIERS
      • TABLE 6: MAIN SEPARATION INSTRUMENT SUPPLIERS
  • DETECTION
    • MASS SPECTROMETRY
      • TABLE 7: MAIN MASS SPECTROSCOPY SUPPLIERS FOR LIFE SCIENCES
      • Direct Injection
      • Mass Spectrometry Imaging
      • Mass Spectrometry Types
      • Ion Trap
      • Quadrupole
      • Time-of-Flight Mass Spectrometers
        • TABLE 8: LEADING MASS SPECTROSCOPY SYSTEMS
    • NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY
    • NUCLEAR MAGNETIC RESONANCE VERSUS MASS SPECTROSCOPY
  • HYPHENATED APPROACHES
  • GAS CHROMATOGRAPHY-MASS SPECTROMETRY
    • SINGLE QUADRUPOLE INSTRUMENTS
    • TIME OF FLIGHT INSTRUMENTS
  • LIQUID CHROMATOGRAPHY MASS SPECTROSCOPY
  • CAPILLARY ELECTROPHORESIS-MASS SPECTROSCOPY
    • TABLE 9: COMMON HYPHENATED PLATFORMS IN METABOLOMIC RESEARCH
  • EMERGING DETECTION TECHNOLOGIES
    • MATRIX-ASSISTED LASER DESORPTION/IONIZATION
    • FOURIER TRANSFORM MASS SPECTROSCOPY
    • FOLDED FLIGHT PATH
    • COMPREHENSIVE TWO-DIMENSIONAL GAS CHROMATOGRAPHY TIME-OF-FLIGHT MASS SPECTROSCOPY
    • MULTIPLE REACTION MONITORING
      • Targeted Untargeted Approach
      • Capillary Electrophoresis Mass Spectroscopy with Sheathless Interfaces
    • PROTEOMIC USE
      • Proteomics
    • METALLOMICS OVERVIEW
      • Tools Used in Metallomics
  • ANALYTICAL EQUIPMENT MARKET
    • TABLE 10: GLOBAL MASS SPECTROMETRY MARKET, THROUGH 2017 ($ BILLIONS)
  • ANALYTICAL EQUIPMENT USED IN THE METABOLOMIC MARKET
    • TABLE 11: GLOBAL ANALYTICAL EQUIPMENT USED IN THE METABOLOMIC MARKET, THROUGH 2020 ($ MILLIONS)

CHAPTER 5 - ASSAY COMPONENTS AND KITS FOR METABOLOMICS

  • TARGETED METABOLOMICS
  • CHAPTER SCOPE
  • ASSAYS OVERVIEW
  • BACKGROUND ON ASSAYS AND ASSAY KITS
  • BIOCHEMICAL ASSAYS
    • CELL-BASED ASSAYS
    • CELL-BASED ASSAY TYPES
    • ASSAY READOUT: OVERVIEW OF DETECTION
    • CELL TYPES USED IN CELL-BASED ASSAYS
      • Immortalized Cell Lines and Primary Cells for Screening
      • Stem Cells at Scale
        • Cellular Dynamics Inc.
  • ASSAY COMMERCIAL CONSIDERATIONS
    • MICROPLATE PLATFORM
    • STANDARDS SETTING
    • CONTINUOUS INNOVATION
    • MICROPLATE READERS
  • ASSAY DETECTION OVERVIEW
    • FLUORESCENCE AS A DRIVER
    • HIGH-CONTENT SCREENING
      • Imaging Advances
      • Future Vision for High-Content Screening
        • TABLE 12: HIGH-CONTENT SCREENING SUPPLIERS AND KEY ATTRIBUTES
    • LABEL-FREE PLATFORMS
      • TABLE 13: LABEL-FREE TECHNOLOGIES AND SUPPLIERS
    • ELECTROPHYSIOLOGY
  • COMMERCIAL LANDSCAPE OF CELL-BASED ASSAYS
  • MAJOR ASSAYS TYPES USED IN METABOLOMICS RESEARCH
    • OTHER TYPES
      • TABLE 14: OTHER ASSAY TYPES USED IN METABOLOMIC RESEARCH
    • MAIN CELL METABOLISM ASSAY APPLICATIONS
      • TABLE 15: MAIN CELL METABOLISM ASSAY APPLICATIONS
  • ASSAYS USED IN METABOLISM
    • ADENOSINE TRIPHOSPHATE
    • ENZYME ROLE
      • Phosphofructokinase
      • 2-Phosphoglycerate
  • OXIDATION AND REDUCTION REACTIONS
    • DEHYDROGENASES
    • ELECTRON TRANSPORT CHAIN
    • OXIDATIVE AND SUBSTRATE-LEVEL PHOSPHORYLATION
    • GLYCOLYSIS
    • KREBS CYCLE
    • METABOLITE ASSAYS
    • ACETYL COA
    • NICOTINAMIDE ADENINE DINUCLEOTIDE AND NADH FADH2
      • Nicotinamide Adenine Dinucleotide Assays
    • OXIDATIVE STRESS ASSAYS
      • TABLE 16: ASSAYS COMMONLY USED IN METABOLOMICS
  • DRUG DISCOVERY USES
    • DRUG DISCOVERY DRIVERS
    • MITOCHONDRIA OPPORTUNITY
    • MITOCHONDRIAL FUNCTION AND CELL METABOLISM
    • MITOCHONDRIAL TOXICITY
      • TABLE 17: MAJOR CATEGORIES OF ASSAYS USED IN METABOLOMICS FOR DRUG DISCOVERY
  • TOOLS AND TECHNOLOGIES
    • TRADITIONAL METHODS
    • OTHER TECHNOLOGIES
  • NEW ANALYSIS TOOLS
    • BIOMARKER ASSAYS
    • FLUORESCENT DYES
    • BIOSENSING TECHNOLOGY
  • ADOPTION TRENDS
    • CANCER
    • OXYGEN CONSUMPTION ASSAY
    • SEAHORSE METABOLIC ANALYZERS
  • ASSAYS IN RELATED APPLICATIONS
    • TABLE 18: OTHER ASSAYS COMMONLY USED ALONGSIDE METABOLOMIC ASSAYS
  • CYTOTOXICITY: A MAJOR CATEGORY
    • CYTOTOXIC AND/OR CYTOSTATIC IMPACTS
    • SCREENING STRATEGIES
  • PERMEABILITY ASSAYS FOR CELL VIABILITY AND SURVIVAL
    • LACTATE DEHYDROGENASE ENZYME RELEASE ASSAYS
    • DYE UPTAKE
    • NEUTRAL RED UPTAKE FOR CELL SURVIVAL ASSAYS
    • ADVANTAGES AND DISADVANTAGES
  • METABOLIC ASSAYS FOR CELL VIABILITY AND SURVIVAL
    • MTT ASSAY
    • ADENOSINE TRIPHOSPHATE ASSAY
    • DISADVANTAGES OF METABOLIC ASSAYS
    • FLUOROMETRIC APPROACHES
    • ALTERED CELL ADHESION
  • ASSAYS FOR CELL DEATH
    • APOPTOSIS VERSUS NECROSIS
    • CASPASE ACTIVATION
    • MEMBRANE RESIDUES
    • CYTOCHROME C RELEASE FROM MITOCHONDRIA
  • ASSAYS FOR CYTOSTATIC OR LONG-TERM IMPACT
    • CLONOGENIC CELL SURVIVAL ASSAY
  • MULTIPLEX ASSAYS
  • COMPOSITE SCREENING STRATEGIES
  • HIGH THROUGHPUT
  • CORRELATION WITH GENE-EXPRESSION DATA
  • TOXICOLOGY AND ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION ASSAYS
  • ACUTE TOXICITY
    • CYTOTOXICITY ASSAY KIT
  • CHRONIC AND REPEATED DOSE TOXICITY
    • SUB-CHRONIC STUDIES
    • ACCUMULATION AND FREQUENCY OF EXPOSURE
    • DOSAGE LEVELS
    • DURATION
    • REVERSIBILITY
    • ANALYSIS
    • DEVELOPMENT OF REPEATED DOSE TOXICITY TESTING IN VITRO
  • CARCINOGENICITY AND GENOTOXICITY
    • IN VITRO METHODS: BACKGROUND AND RECENT DEVELOPMENTS
    • REGULATORY VERSUS DRUG DEVELOPMENT APPLICATIONS
    • AMES TEST
    • IN VITRO MICRONUCLEUS TEST
  • EFFORTS TO REDUCE FALSE POSITIVES
  • RECENT INNOVATIONS FOR SCREENING
    • METABOLITE ASSESSMENT
  • FUTURE CHALLENGE: NON-GENOTOXIC CARCINOGENS
    • REPRODUCTIVE AND DEVELOPMENTAL TOXICITY
    • FOLLOWING THE REPRODUCTIVE CYCLE
    • EMBRYOTOXICITY
    • MALE REPRODUCTIVE TOXICITY
    • FEMALE REPRODUCTIVE TOXICITY
    • DEVELOPMENTAL AND REPRODUCTIVE TOXICOLOGY TESTING TYPES
    • ZEBRAFISH MODEL FOR DEVELOPMENTAL TOXICITY SCREENING
    • COMBINATIONS OF ZEBRAFISH AND STEM CELLS
    • BIOMEDICAL FRONTIERS: MALE TESTIS
  • ENDOCRINE DISRUPTOR SCREENING
    • ENVIRONMENTAL TOXICOLOGY IMPACTS IN VITRO METHODS
    • U.S. ENVIRONMENTAL PROTECTION AGENCY'S ENDOCRINE DISRUPTOR SCREENING PROGRAM
      • TABLE 19: IN VITRO AND IN VIVO ASSAY TESTS IN THE TIER 1 SCREENING BATTERY, 2013
    • HIGH-PRODUCTION VOLUME CHEMICALS
    • TOXCAST AND TOX 21 INITIATIVES
    • FUTURE CHALLENGE: THYROID DISRUPTION
    • BG1 ASSAY
  • LIVER TOXICITY APPLICATIONS
  • IMPORTANCE OF TWO-DIMENSIONAL VERSUS THREE-DIMENSIONAL SYSTEMS
  • IMMUNE MEDIATED DRUG-INDUCED LIVER INJURY
  • KIDNEY TOXICITY
    • FUTURE CHALLENGE: STEM CELL-DERIVED KIDNEY CELLS
  • ABSORPTION, DISTRIBUTION, METABOLISM AND EXCRETION AND TOXICOKINETICS
    • IN VITRO DEVELOPMENTS
    • UNMET NEED FOR METABOLIC TRANSFORMATION
    • IN VITRO METABOLISM OFFERINGS
    • METABOLISM BY CYP450 ENZYMES: REACTION PHENOTYPING STUDIES
    • CYPROTEX
  • MICROFLUIDICS AND ORGANS-ON-A-CHIP
  • SUMMARY
  • COMMERCIAL CONSIDERATIONS
    • CELL-BASED ASSAY MARKET
    • GENOME SEQUENCING MARKET
    • MARKET
      • TABLE 20: GLOBAL RESEARCH ASSAYS USED IN METABOLOMICS MARKET, THROUGH 2020 ($ MILLIONS)

CHAPTER 6 - BIOINFORMATICS IN METABOLOMICS

  • OVERVIEW
  • BIOINFORMATIC PROCESSES
    • TABLE 21: BIOINFORMATIC PROCESSES FOR METABOLOMICS
  • DATA COMPOSITION ANALYSIS AND PROCESSING
    • DATA COMPOSITION ANALYSIS
      • XCMS
      • Others
        • TABLE 22: METABOLOMIC OPEN-ACCESS DATA-PROCESSING TOOLS
  • DATA REDUCTION AND INTEGRATION
    • STATISTICAL APPROACHES AND CHALLENGES
    • GENOMICS INFLUENCE
    • METABOLOMIC METHODS
    • PRINCIPAL COMPONENT ANALYSIS
      • Upgrading Principal Component Analysis
    • FUNCTIONAL CLASSIFIERS BASED ON PATHWAYS AND NETWORKS
    • PATHWAY MAPS
    • KNOWLEDGE-BASED APPROACHES
  • DATA MODELING
    • RECONSTRUCTION
    • VERIFICATION
    • NETWORK SIMULATION
  • DATA VISUALIZATION
  • DATABASE CURATION AND MANAGEMENT
  • METABOLOMICS PUBLIC RESOURCES
    • TABLE 23: METABOLOMIC PUBLIC RESOURCES
  • SELECT DESCRIPTIONS
    • DAVID WISHART RESEARCH GROUP
    • METLIN
    • KYOTO ENCYCLOPEDIA OF GENES AND GENOMES
    • OTHERS
      • TABLE 24: OTHER METABOLOMIC BIOINFORMATIC RESOURCES
  • COMMERCIAL MARKET STRUCTURE
    • VENDORS AND EQUIPMENT MANUFACTURERS
    • BIOINFORMATICS COMPANIES AND SYSTEMS BIOLOGY PLAYERS WITH A SPECIFIC FOCUS ON METABOLOMICS RESEARCH
      • Thomson Reuters' Metadrug
    • GENEDATA SCREENER AND EXPRESSIONIST
    • QIAGEN
    • INGENUITY PATHWAY ANALYSIS
    • BMSYSTEMS
  • COMPANIES THAT DEVELOP THEIR OWN SOFTWARE
    • METABOLON
    • CHENOMX
    • LIMITATIONS
    • UNMET NEEDS
    • DATA STANDARDIZATION
  • MARKET
    • TABLE 25: GLOBAL BIOINFORMATIC TOOLS USED IN THE METABOLOMIC MARKET, THROUGH 2020 ($ MILLIONS)

CHAPTER 7 - CLINICAL BIOMARKERS

  • OVERVIEW
    • TABLE 26: MAJOR CLINICAL METABOLOMIC APPLICATIONS
  • BIOMARKER CHALLENGES
  • PROGRESS FROM PROTEOMICS
  • METABOLOMIC ADVANTAGE
  • APPLICATION ADOPTION
    • GENOMICS LEADERSHIP
    • METABOLOMICS' KEY ROLE
  • MAJOR CLINICAL APPLICATIONS
    • INBORN ERRORS OF METABOLISM
    • BACKGROUND
      • Amino Acid Disorders
      • Fatty Acid Oxidation Disorders
      • Organic Acid Disorders
    • ONSET AND SEVERITY
    • EXAMPLES OF INBORN ERRORS OF METABOLISM
    • INCIDENCE AND TESTING
  • PHARMACOGENOMICS
    • PHARMACOGENOMICS ADOPTION
    • CURRENT SUCCESSES IN PHARMACOGENOMICS
      • Warfarin
      • Simvastatin
      • Cancer Drugs
        • Cisplatin Chemotherapy
        • Anthracyclines
  • LIVER ENZYME CYP2C19
  • CLOPIDIGREL
  • CODEINE
  • HUMAN LEUKOCYTE ANTIGEN B
  • CARBAMAZEPINE
  • AZATHIOPRINE
  • MENTAL HEALTH
    • ANTIDEPRESSANTS
  • SEROTONIN
  • CATECHOL METHYL TRANSFERASE
  • PHARMACOKINETIC AND PHARMACODYNAMIC GENES
  • COMMERCIAL EXAMPLE
  • CHALLENGES AND FUTURE DIRECTIONS
    • VALIDATION
  • CANCER
    • CANCER HALLMARKS
    • CANCER METABOLISM OVERVIEW
    • CANCER GLUCOSE METABOLISM
    • CANCER GLUTAMINE METABOLISM
    • CANCER SERINE AND GLYCINE METABOLISM
    • ONE-CARBON METABOLISM
    • CANCER AND THE FOLATE CYCLE
      • Folic Acid
    • METHIONE CYCLE
    • CANCER AND GLUTATHIONE CYCLE
    • LIPID METABOLISM
    • CANCER DRUG APPLICATIONS
      • Folate Agonist Drugs
      • Nucleotide Metabolism
      • Targeting Metabolic Enzymes in Cancer
      • Enzyme Starvation
      • Mitochondrial Folate Metabolism
      • In Vitro Models
      • Path Forward
  • CARDIOVASCULAR AND METABOLIC DISEASE
    • APPLICATIONS
    • PLANNED MYOCARDIAL ISCHEMIA AND INFARCTION
    • EXERCISE STRESS TESTING
    • ALCOHOL SEPTAL ABLATION
    • NITRIC OXIDE METABOLIC PATHWAY
    • ANTHRACYCLINE-INDUCED CARDIOTOXICITY
    • ATRIAL FIBRILLATION
    • DETECTING HEART FAILURE VERSUS B-TYPE NATRIURETIC PEPTIDE
    • PULMONARY HYPERTENSION
      • Pulmonary Hypertension as Mitochondria Dysfunction
      • Pulmonary Hypertension and Insulin Resistance
    • ATHEROSCLEROSIS RISK
      • Lipid Profiles
      • Cholesterol
      • Particles
    • CHOLESTEROL TESTING CLINICAL USES AND MARKET
    • STATINS
    • POSSIBLE ADVERSE DRUG REACTIONS
    • SERUM MARKERS
    • STATIN DOSE MARKER
    • COADMINISTRATION
    • METABOLIZATION DIFFERENCES
    • GENETIC VARIABILITY
    • LIPID PROFILE
    • BEYOND STATINS TO MULTIMARKER APPROACH
      • Jupiter Trial
      • Jupiter Expands Statin Use
      • Jupiter Also Raises Diabetes Risk
      • Guidelines
    • SYSTEMIC AND VASCULAR INFLAMMATION
      • High-Sensitivity C-Reactive Protein
      • Myeloperoxidase
      • Lipoprotein-Associated Phospholipase-A2
    • ADVANCED LIPID TESTING
      • Apolipoprotein B and A1 (ApoA1)
      • Small-Dense LDL
      • Lipoprotein (a)
      • HDL2b
      • Particle Type
    • COMPANIES OFFERING ADVANCED LIPID TESTING
    • LIPOSCALE TEST
    • PRIMARY CARE PHYSICIANS
    • CLEVELAND HEARTLAB
    • NON-FASTING TRIGLYCERIDES
    • METABOLOMIC APPLICATIONS
    • LIPIDOMICS
    • CHOLINE METABOLISM
    • ACYLCARNITINES
      • Trimethylamine N-oxide
    • MICROFLORA-DERIVED CHOLINE METABOLITES
    • LINK WITH GUT MICROFLORA
    • DIABETES AND PRE-DIABETES
      • Insulin Resistance
      • Link with Obesity not Conclusive
    • TOOLS TO DETECT INSULIN RESISTANCE
    • COMPANIES OFFERING INSULIN-RESISTANCE TESTING
    • OTHER INSULIN-RESISTANCE TESTING
      • Branched-Chain Amino Acids: Insulin Resistance via Exercise Stress Testing
      • Branched-Chain Amino Acids and Gastric Bypass
  • LIVER DISEASES
    • METHYLATION DEFICIENCY
    • FOLATE DEFICIENCY
    • CLINICAL LIVER DISEASE
      • Diagnosis
      • Treatment
      • Research
      • Progress on Non-Alcoholic Fatty Liver Disease
      • OWL
      • European Association for the Study of the Liver
    • APPLICATIONS IN LIVER RESEARCH
      • Liver Metabolism Overview
      • Liver Function and Structure
        • Hepatocytes or Parenchymal Cells
        • Specialized Liver Endothelial Cells
        • Non-Parenchymal Stellate and Kupffer Cells
        • Morphogen Signaling
      • In Vitro Applications
      • Drug-Induced Liver Injury
        • Kiyatec
      • Liver Inflammation Models
        • Hepregen
      • Liver Regeneration
        • Achieving Hepatocyte Expansion Still Elusive
        • Cell Types
        • HepaRG
          • TABLE 27: ORGANIZATIONS OFFERING IMMORTALIZED CELL LINES, 2013
      • Human and Other Primary Hepatocytes
        • TABLE 28: COMPANIES OFFERING PRIMARY CELLS, 2013
      • Stem Cell-Derived Hepatocytes
        • RAFT for iPS Hepatocytes Longevity
        • Hepatotoxicity Screening Library
      • Stem Cell Companies
      • TABLE 29: COMPANIES OFFERING STEM CELLS FOR LIVER SAFETY TESTING AND RESEARCH, 2013
    • TOXICITY STUDIES AND NON-PARENCHYMAL CELLS AS DRIVERS OF IN VITRO DEVELOPMENT
    • TYPICAL END POINTS
    • KEY REQUIREMENTS
      • Cell-Cell Contacts Key for Differentiation and Functionality
      • Oxygen Supply
      • Co-Culture
      • Developments
      • Challenges
      • Benefits of Three-Dimensional Spheroids
      • High-Content Imaging and Analysis
      • Microfluidics
        • Dielectrophoretic Forces
        • HepaChip
        • Learnings from Microfluidics
        • Self-Organizing Systems
  • COMMERCIAL CONSIDERATIONS
    • LABORATORY-DEVELOPED TESTS
      • TABLE 30: LABORATORY-DEVELOPED TEST PROVIDERS, 2015
    • CLEVELAND HEARTLAB
    • MARKET
      • TABLE 31: GLOBAL CLINICAL BIOMARKERS USED IN METABOLOMICS MARKET, THROUGH 2020 ($ MILLIONS)

CHAPTER 8 - COMPANY PROFILES

  • ABCAM
  • AGILENT TECHNOLOGIES INC.
  • ATHEROTECH DIAGNOSTICS LAB
  • BG MEDICINE INC.
  • BIOVISION INC.
  • CALITHERA BIOSCIENCES INC.
  • CHENOMX
  • CITOXLAB
  • CLEVELAND HEARTLAB INC.
  • CLINMET INC.
  • COURTAGEN LIFE SCIENCES INC.
  • CYPROTEX PLC
  • EMD MILLIPORE
  • EXALENZ BIOSCIENCE LTD,
  • GENOMIND INC.
  • LECO CORP.
  • LUMINEX CORP.
  • METABOLOMIC DIAGNOSTICS
  • METABOLOMIC TECHNOLOGIES INC.
  • METABOLOMX
  • METABOLON INC.
  • METANOMICS GMBH
  • ONE WAY LIVER GENOMICS, S.L
  • PHENOMENOME DISCOVERIES INC.
  • PROMEGA CORP.
  • QIAGEN GMBH
  • SEAHORSE BIOSCIENCE
  • SIGMA-ALDRICH
  • STEMINA BIOMARKER DISCOVERY INC.
  • THERMO FISHER SCIENTIFIC
  • XENOTECH

LIST OF TABLES

  • SUMMARYTABLE: GLOBAL METABOLOMIC MARKET BY APPLICATION, THROUGH 2020 ($ MILLIONS)
    • TABLE 1: HUMAN METABOLOME PROJECT AND DATABASE, 2006-2013
    • TABLE 2: CELLULAR RESPIRATION STAGES
    • TABLE 3: FACTORS IMPACTING ENZYME ACTIVITY
    • TABLE 4: PUBLICATIONS USING KEYWORD METABOLOMICS IN THE SEARCH, 2002-2014 (TOTAL PER YEAR)
    • TABLE 5: TYPICAL ANALYTICAL METRABOLOMIC PROCESS STEPS
    • TABLE 6: MAIN SEPARATION INSTRUMENT SUPPLIERS
    • TABLE 7: MAIN MASS SPECTROSCOPY SUPPLIERS FOR LIFE SCIENCES
    • TABLE 8: LEADING MASS SPECTROSCOPY SYSTEMS
    • TABLE 9: COMMON HYPHENATED PLATFORMS IN METABOLOMIC RESEARCH
    • TABLE 10: GLOBAL MASS SPECTROMETRY MARKET, THROUGH 2017 ($ BILLIONS)
    • TABLE 11: GLOBAL ANALYTICAL EQUIPMENT USED IN THE METABOLOMIC MARKET, THROUGH 2020 ($ MILLIONS)
    • TABLE 12: HIGH-CONTENT SCREENING SUPPLIERS AND KEY ATTRIBUTES
    • TABLE 13: LABEL-FREE TECHNOLOGIES AND SUPPLIERS
    • TABLE 14: OTHER ASSAY TYPES USED IN METABOLOMIC RESEARCH
    • TABLE 15: MAIN CELL METABOLISM ASSAY APPLICATIONS
    • TABLE 16: ASSAYS COMMONLY USED IN METABOLOMICS
    • TABLE 17: MAJOR CATEGORIES OF ASSAYS USED IN METABOLOMICS FOR DRUG DISCOVERY
    • TABLE 18: OTHER ASSAYS COMMONLY USED ALONGSIDE METABOLOMIC ASSAYS
    • TABLE 19: IN VITRO AND IN VIVO ASSAY TESTS IN THE TIER 1 SCREENING BATTERY, 2013
    • TABLE 20: GLOBAL RESEARCH ASSAYS USED IN METABOLOMICS MARKET, THROUGH 2020 ($ MILLIONS)
    • TABLE 21: BIOINFORMATIC PROCESSES FOR METABOLOMICS
    • TABLE 22: METABOLOMIC OPEN-ACCESS DATA-PROCESSING TOOLS
    • TABLE 23: METABOLOMIC PUBLIC RESOURCES
    • TABLE 24: OTHER METABOLOMIC BIOINFORMATIC RESOURCES
    • TABLE 25: GLOBAL BIOINFORMATIC TOOLS USED IN THE METABOLOMIC MARKET, THROUGH 2020 ($ MILLIONS)
    • TABLE 26: MAJOR CLINICAL METABOLOMIC APPLICATIONS
    • TABLE 27: ORGANIZATIONS OFFERING IMMORTALIZED CELL LINES, 2013
    • TABLE 28: COMPANIES OFFERING PRIMARY CELLS, 2013
    • TABLE 29: COMPANIES OFFERING STEM CELLS FOR LIVER SAFETY TESTING AND RESEARCH, 2013
    • TABLE 30: LABORATORY-DEVELOPED TEST PROVIDERS, 2015
    • TABLE 31: GLOBAL CLINICAL BIOMARKERS USED IN METABOLOMICS MARKET, THROUGH 2020 ($ MILLIONS)

LIST OF FIGURES

  • SUMMARY FIGURE: GLOBAL METABOLOMIC MARKET BY APPLICATION, 2014-2020 ($ MILLIONS)
    • FIGURE 1: PUBLICATIONS USING KEYWORD METABOLOMICS IN THE SEARCH, 2002-2014 (TOTAL PER YEAR)
Back to Top